Polaris Genomics

06/15/2026

Later this month, national PTSD screening initiatives will encourage individuals to reflect on symptoms, seek support, and begin conversations about trauma and mental health. These campaigns matter because too many people continue to suffer in silence — often for years before receiving appropriate evaluation or care.

PTSD is not confined to one community. While military and Veteran populations remain central to PTSD research and advocacy because of elevated occupational exposure rates, civilians represent a substantial portion of those living with trauma-related disorders. Survivors of abuse, violence, severe illness, accidents, caregiving stress, and community trauma are frequently under-recognized despite significant clinical burden.

Current PTSD screening approaches primarily depend on self-reported symptom inventories and clinical interviews. These tools are valuable and evidence-based, but psychiatry continues to face broader challenges around objectivity, reproducibility, and early detection.

At Polaris Genomics, our work is centered on helping advance biologically based approaches to mental health assessment. We are focused on developing tools that can complement traditional clinical evaluation with objective molecular data, with the long-term goal of improving precision, reducing stigma, and supporting earlier intervention.

The future of mental healthcare will require both compassion and better measurement science. Learn more about our mission at PolarisGenomics.com.

05/29/2026

June is National PTSD Awareness Month and nationwide, trauma-related disorders affect far more than military populations alone. PTSD impacts survivors of interpersonal violence, medical trauma, childhood adversity, accidents, natural disasters, first responders, healthcare workers, and civilians across every demographic. According to the National Center for PTSD, approximately 6% of U.S. adults will experience PTSD at some point in their lives. Women are statistically more likely to develop PTSD than men, though the condition affects individuals across all populations and professions.

National awareness campaigns — including those led by the VA and other advocacy organizations — have helped elevate public understanding of PTSD and reduce stigma surrounding mental health care. They have also highlighted an ongoing clinical challenge: PTSD diagnosis and screening still rely heavily on subjective symptom reporting, patient recall, and clinician-administered assessments.

At Polaris Genomics, we believe mental healthcare deserves the same commitment to objective biological measurement that exists throughout the rest of medicine. Our mission is to advance biologically based screening tools that may help support earlier identification, improve clinical confidence, and enable more personalized approaches to care.

Awareness is essential. But improving outcomes will also require innovation in how we detect, evaluate, and understand trauma-related conditions at the biological level. Learn more about our blood-based screening tool, PTS-ID at www.PolarisGenomics.com.

Polaris Genomics is charting the course for researchers who want to bring biological clarity and objectivity to the assessment, diagnosis, and treatment of

05/19/2026

Mental Health Awareness Month reminds us that mental health is deeply human — but it is also deeply biological.

This year, NAMI’s 2026 Mental Health Awareness Month campaign centers on a powerful truth: “Stigma grows in silence. Healing begins in community.”

At Polaris Genomics, we believe healing also begins with understanding.

For too long, mental health conditions have been assessed primarily through observation and self-reported symptoms alone. Our work is focused on advancing biological clarity and objective measurement in neuropsychiatric research through genomics and biomarker discovery.

By helping researchers better understand the biological underpinnings of mental and brain health, we move closer to more personalized diagnostics, more targeted therapies, and better outcomes for patients and families.

Awareness matters. Advocacy matters. Community matters. And science matters too.

This Mental Health Awareness Month, we stand with the researchers, clinicians, advocates, families, and individuals working to transform mental health care through compassion, innovation, and evidence-based discovery.

03/27/2026

At Polaris Genomics, we are committed to bringing greater objectivity and biological insight into the diagnosis and treatment of mental health conditions.

Our neuropsychiatric biomarker platform is designed to support CNS drug development—particularly in areas such as PTSD, depression, and traumatic brain injury (TBI). By combining genomics with advanced artificial intelligence, we aim to uncover the biological underpinnings of mental health and enable more precise diagnostics and therapeutics.

At the core of our work is the ADAPT Neuropsychiatric Biomarker Discovery Platform™, which integrates a targeted gene panel with deep analytics to generate actionable biomarker signatures from simple blood samples.

We are actively seeking to engage with mid-sized pharmaceutical companies, especially those in the early stages of psychedelic drug development, for both short-term projects and long-term strategic collaborations.

If you are interested in exploring a potential partnership, feel free to reach out to our Director of Strategic Partnerships to arrange an introductory discussion with our science team. Inquire with Sudhama Swamy at [email protected].

We believe it’s time to fundamentally change how mental health conditions are addressed, diagnosed, and treated—and we welcome like-minded partners on this journey.

03/26/2026

Women are twice as likely as men to experience anxiety disorders, including generalized anxiety and panic disorder, reflecting a complex interplay of hormonal biology, stress exposure, and social determinants of health. (Psychiatry) Through the ADAPT Platform, Polaris Genomics is working to identify neuropsychiatric biomarkers that can support better research models, enable drug discovery, and advance precision companion diagnostics for conditions like anxiety.

03/18/2026

Women's history and women's present: Did you know depression is the most common mental health condition among women? Women experience major depressive disorder at roughly twice the rate of men. Biological, hormonal, and social stressors all contribute and underscore the need for objective insights. Polaris Genomics' ADAPT Platform is designed for biomarker discovery and utilization for mental health research, diagnostics, and treatment. https://polarisgenomics.com/our-platform/adapt/

03/16/2026

This Women’s History Month, we’re proud to spotlight our Chief Medical Officer, Dr. Anne Naclerio, whose leadership is helping advance biomarker-driven approaches to neuropsychiatric health. Women represent a growing force in biomedical innovation, yet they remain underrepresented in senior leadership across biotech and pharma. At Polaris Genomics, leaders like Anne are guiding the development of the ADAPT Platform to accelerate discovery of objective biomarkers that can transform how mental health conditions are studied, diagnosed, and treated. Learn more about Anne’s extensive experience here: https://polarisgenomics.com/about-us/

03/10/2026

Women’s history - and lived experience - we should all talk more about: Did you know women are about twice as likely as men to develop PTSD, with lifetime prevalence around 8% in women vs. 4% in men? It is often linked to higher exposure to trauma types such as sexual assault or intimate partner violence.

Polaris Genomics’ first-of-its-kind product, PTS-ID™, is an objective and biomarker based PTSD screening tool. PTS-ID™ is 2-3 times more sensitive to measures indicative of PTSD than current self-report measures alone. We're committed to reducing suffering in silence.

https://polarisgenomics.com/our-platform/pts-id/

02/27/2026

Wrapping up American Heart Month, we hope to spread awareness that PTSD significantly increases the risk of cardiovascular disease—comparable to risks from smoking or high cholesterol—by triggering chronic stress, high blood pressure, inflammation, and heart rate variability. Individuals with PTSD have a ~50% higher risk of heart failure and a doubled risk of stroke. This Harvard Medical School article explores therapies and methods for stress reduction: https://www.health.harvard.edu/heart-health/when-fear-strikes-the-heart-post-traumatic-stress-disorder

02/17/2026

Our week-long visit to healthcare events in was nothing short of energizing. The Future of Mental Health Care looks incredibly promising—and massive—in the Middle East. To put this to context, there were nearly 800 exhibitors from over 40 countries and welcome more than 35,000 professional visits.

From advanced diagnostics innovators to lab equipment suppliers representing the breadth of the region, the diversity and quality of exhibitors was impressive. More importantly, the conversations were purposeful. There is a clear hunger across the MENA region to offer robust diagnostic solutions for mental health conditions and to build population-scale genomics programs tailored to regional needs.

We met multiple potential partners who are not only commercially motivated, but mission-driven—seeking to transform healthcare delivery through precision and . The momentum is real, and the timing is right.

The growth potential in Abu Dhabi and Dubai is particularly striking. The infrastructure, regulatory forward-thinking, and investment appetite create a uniquely fertile ground for scaling precision medicine initiatives.

A highlight of the visit was touring Free Zone, which stands as a symbol of innovation-driven economic development. Seeing firsthand how life sciences and biotech companies are being supported reinforced our confidence that this region is building for long-term impact.

It was also meaningful visit for Tshaka Cunningham, our Chief of R&D, Charles Cathlin, our CEO, and Sudhama Swamy, our Director of Strategic Partnerships, who experienced in real time the depth of opportunity to grow Polaris Genomics through strategic regional partnerships.

Now it is about taking those small, deliberate steps that can translate into meaningful, long-term impact.

Polaris Genomics is here to stay in this region—and to grow—in the Middle East. The week was not just exciting; it was an eye-opener to the scale of transformation underway.

Wait and watch for more exciting news from us in the coming weeks.